Boc-D-Serine methyl ester

We are Boc-D-Serine methyl ester CAS:95715-85-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: Boc-D-Serine methyl ester
CAS.NO: 95715-85-8
Molecular Formula: C9H17NO5
Molecular Weight: 219.23500

Synonyms:
Methyl N-(tert-butoxycarbonyl)-D-serinate
methyl (2R)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
Methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-D-serinate
MFCD00270516
D-Serine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester
Boc-D-Ser-OMe

Physical and Chemical Properties:
Density: 1.149g / cm3
Boiling point: 354.3ºC at 760mmHg
Flash point: 168.1ºC
Refractive index: n20 / D 1.453 (lit.)

Specification:
Appearance: Colorless to light yellow liquid
Purity:≥99%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at 0-5ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.3-oxo-N-[4-(3-oxobutanoylamino)phenyl]butanamide A new case of coronavirus has been reported in the United Arab Emirates, the country’s fifth, the Ministry of Health and Prevention announced on Saturday.3-Cyanobenzylchloride CAS:64407-07-4 The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.1-hidroxipireno CAS:5315-79-7 The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.“With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”